Drug Delivery Technology Development in Canada
Canada continues to have a rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community.
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_45503 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03928-005-6 | ||
| 020 | |a 9783039280056 | ||
| 020 | |a 9783039280049 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03928-005-6 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Wasan, Kishor |4 auth | |
| 700 | 1 | |a Badea, Ildiko |4 auth | |
| 245 | 1 | 0 | |a Drug Delivery Technology Development in Canada |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 electronic resource (352 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Canada continues to have a rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a encapsulation | ||
| 653 | |a biodistribution | ||
| 653 | |a pharmaceutics | ||
| 653 | |a targeted therapies | ||
| 653 | |a gambogic acid | ||
| 653 | |a GE11 peptide | ||
| 653 | |a formulation and dosage form development | ||
| 653 | |a transient modulation | ||
| 653 | |a ROESY NMR spectroscopy | ||
| 653 | |a bioaccessibility | ||
| 653 | |a polymeric micelle | ||
| 653 | |a pharmacological Inhibitors of HIF-1 and STAT3 | ||
| 653 | |a nanoparticles | ||
| 653 | |a Vitamin D | ||
| 653 | |a drug discovery | ||
| 653 | |a EGFR-targeted therapy | ||
| 653 | |a translational research | ||
| 653 | |a clinical trials | ||
| 653 | |a doxorubicin | ||
| 653 | |a dissolution | ||
| 653 | |a drug development | ||
| 653 | |a permeation enhancers | ||
| 653 | |a Canada | ||
| 653 | |a plant | ||
| 653 | |a primary central nervous system lymphomas | ||
| 653 | |a photostabilizers | ||
| 653 | |a head and neck squamous cell carcinoma | ||
| 653 | |a mouse models | ||
| 653 | |a drug delivery systems | ||
| 653 | |a melphalan | ||
| 653 | |a hypoxia-induced chemoresistance | ||
| 653 | |a skin | ||
| 653 | |a virus | ||
| 653 | |a circadian clock | ||
| 653 | |a child friendly formulation | ||
| 653 | |a adenanthin | ||
| 653 | |a co-delivery | ||
| 653 | |a canola oil deodorizer distillate | ||
| 653 | |a Metaplex | ||
| 653 | |a innovation | ||
| 653 | |a controlled drug delivery | ||
| 653 | |a nifedipine | ||
| 653 | |a radiolabeling | ||
| 653 | |a amphotericin B | ||
| 653 | |a biological barriers | ||
| 653 | |a blood-brain barrier (BBB) | ||
| 653 | |a biologicals | ||
| 653 | |a lipid nanoparticles | ||
| 653 | |a oral formulation | ||
| 653 | |a phytosterols | ||
| 653 | |a medical devices | ||
| 653 | |a chronotherapy | ||
| 653 | |a oral | ||
| 653 | |a cationic gemini surfactant | ||
| 653 | |a route of administration | ||
| 653 | |a drug delivery | ||
| 653 | |a intra-arterial chemotherapy | ||
| 653 | |a developing world | ||
| 653 | |a sustained delivery | ||
| 653 | |a water miscible solvents | ||
| 653 | |a combination therapy | ||
| 653 | |a antibodies | ||
| 653 | |a throughput | ||
| 653 | |a magnetic fields | ||
| 653 | |a liposomes | ||
| 653 | |a medulloblastoma | ||
| 653 | |a drug-resistant melanoma | ||
| 653 | |a rosmarinic acid | ||
| 653 | |a topical formulation | ||
| 653 | |a TNO gastrointestinal model | ||
| 653 | |a gastrointestinal simulator | ||
| 653 | |a malignant gliomas | ||
| 653 | |a transdermal drug delivery | ||
| 653 | |a oral delivery | ||
| 653 | |a precision medicine | ||
| 653 | |a 3D spheroid | ||
| 653 | |a flavonoids | ||
| 653 | |a staurosporine | ||
| 653 | |a DOX-Vit D | ||
| 653 | |a loading gradients | ||
| 653 | |a bacteriophage | ||
| 653 | |a phospholipid complex | ||
| 653 | |a triggered drug release | ||
| 653 | |a HIF-1 | ||
| 653 | |a phage display | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a emulsion | ||
| 653 | |a quercetin | ||
| 653 | |a cisplatin | ||
| 653 | |a parasitic infections | ||
| 653 | |a remote loading | ||
| 653 | |a HAV6 cadherin peptide | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a inclusion complex | ||
| 653 | |a tocopherols | ||
| 653 | |a STAT3 | ||
| 653 | |a ultrasound | ||
| 653 | |a liposome | ||
| 653 | |a fungal infections | ||
| 653 | |a magnetic resonance imaging (MRI) | ||
| 653 | |a MG63 | ||
| 653 | |a model orange juice | ||
| 653 | |a radiation | ||
| 653 | |a cancer | ||
| 653 | |a mefloquine | ||
| 653 | |a small molecules | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/1904 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/45503 |7 0 |z DOAB: description of the publication |